Park Jung Woo, Jeong Hyun Cheol, Moon Hyong Woo, Cho Shin Jay, Yang Jong Hyup, Kim Woo Hyun, Bae Woong Jin, Choi Jin Bong, Cho Hyuk Jin, Ha U-Syn, Hong Sung Hoo, Lee Ji Youl, Kim Sae Woong
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Catholic Integrative Medicine Research Institute, The Catholic University of Korea, Seoul, Korea.
World J Mens Health. 2016 Dec;34(3):179-185. doi: 10.5534/wjmh.2016.34.3.179. Epub 2016 Dec 22.
The aim of this study was to investigate the anti-inflammatory and anti-oxidative effects of a multi-herbal formula known as WSY-1075 in the treatment of chronic bacterial prostatitis in a rat model.
Experimental chronic bacterial prostatitis was induced in 32 Wistar rats by instillation of a bacterial suspension (, 10 colony-forming units [CFU]/mL) into the prostatic urethra. After the induction of prostatitis, the rats were randomly divided into one of 4 treatment groups: control (n=8), ciprofloxacin (n=8), WSY-1075 (400 mg/kg) (n=8), and WSY-1075 (400 mg/kg)+ciprofloxacin (n=8). After 4 weeks of treatment, microbiological data from prostate tissue cultures, level of prostatic pro-inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin [IL]-6, and IL-8), anti-oxidant effects (superoxide dismutase [SOD]), and histological findings were noted.
The WSY-1075, ciprofloxacin, and WSY-1075+ciprofloxacin groups showed fewer CFUs in prostate tissue cultures than the control group. The WSY-1075, ciprofloxacin and WSY-1075+ciprofloxacin groups showed statistically significantly lower levels of the pro-inflammatory cytokines TNF-α, IL-6, and IL-8 than the control group. SOD levels in the WSY-1075, ciprofloxacin and WSY-1075+ciprofloxacin groups were significantly higher than in the control group.
This study found that WSY-1075 had anti-microbial effects, anti-inflammatory effects, and anti-oxidative effects in a chronic bacterial prostatitis rat model. We expect the WSY-1075 may be useful for the clinical treatment of chronic bacterial prostatitis.
本研究旨在探讨一种名为WSY - 1075的多草药配方在大鼠慢性细菌性前列腺炎模型治疗中的抗炎和抗氧化作用。
通过向前列腺尿道注入细菌悬液(,10个菌落形成单位[CFU]/mL),在32只Wistar大鼠中诱导实验性慢性细菌性前列腺炎。前列腺炎诱导后,将大鼠随机分为4个治疗组之一:对照组(n = 8)、环丙沙星组(n = 8)、WSY - 1075(400 mg/kg)组(n = 8)和WSY - 1075(400 mg/kg)+环丙沙星组(n = 8)。治疗4周后,记录前列腺组织培养的微生物学数据、前列腺促炎细胞因子(肿瘤坏死因子-α [TNF-α]、白细胞介素[IL]-6和IL-8)水平、抗氧化作用(超氧化物歧化酶[SOD])以及组织学结果。
WSY - 1075组、环丙沙星组和WSY - 1075 +环丙沙星组前列腺组织培养中的菌落形成单位比对照组少。WSY - 1075组、环丙沙星组和WSY - 1075 +环丙沙星组促炎细胞因子TNF-α、IL-6和IL-8的水平在统计学上显著低于对照组。WSY - 1075组、环丙沙星组和WSY - 1075 +环丙沙星组的SOD水平显著高于对照组。
本研究发现WSY - 1075在慢性细菌性前列腺炎大鼠模型中具有抗菌、抗炎和抗氧化作用。我们期望WSY - 1075可能对慢性细菌性前列腺炎的临床治疗有用。